NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free XNCR Stock Alerts $22.48 -1.06 (-4.50%) (As of 05/10/2024 08:55 PM ET) Add Compare Share Share Today's Range$22.36▼$24.2850-Day Range$18.21▼$24.3152-Week Range$16.49▼$28.96Volume473,900 shsAverage Volume699,154 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$36.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Xencor alerts: Email Address Xencor MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside61.3% Upside$36.25 Price TargetShort InterestBearish10.84% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment0.00Based on 15 Articles This WeekInsider TradingSelling Shares$2.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.25) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector181st out of 925 stocksPharmaceutical Preparations Industry73rd out of 430 stocks 4.4 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXencor has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xencor's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.84% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Xencor has recently increased by 7.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 2.2 News and Social Media Coverage News SentimentXencor has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Xencor this week, compared to 2 articles on an average week.Search Interest5 people have searched for XNCR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,152,417.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.25) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest About Xencor Stock (NASDAQ:XNCR)Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More XNCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Stock News HeadlinesMay 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor on Strategic Focus and Strong Financial PositionMay 12, 2024 | americanbankingnews.comWedbush Increases Xencor (NASDAQ:XNCR) Price Target to $36.00May 13, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 11, 2024 | finance.yahoo.comXencor First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comDecoding 6 Analyst Evaluations For XencorMay 10, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on Xencor (XNCR)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xencor on Strong Pipeline and Financials: Anticipated IND Filing and T-cell Engager DevelopmentsMay 10, 2024 | finance.yahoo.comXencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings EstimatesMay 13, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Xencor (XNCR) and Evolent Health (EVH)May 10, 2024 | investorplace.comXNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | businesswire.comXencor Reports First Quarter 2024 Financial ResultsMay 4, 2024 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsMay 3, 2024 | finance.yahoo.comInsider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells SharesApril 16, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For XencorApril 11, 2024 | uk.investing.comXencor names Bart Cornelissen as new CFOApril 10, 2024 | markets.businessinsider.comXencor Appoints Bart Cornelissen As CFOApril 9, 2024 | marketwatch.comXencor Names Bart Cornelissen Chief Financial OfficerApril 9, 2024 | finance.yahoo.comXencor Appoints Bart Cornelissen as Chief Financial OfficerApril 9, 2024 | businesswire.comXencor Appoints Bart Cornelissen as Chief Financial OfficerMarch 16, 2024 | finance.yahoo.comXNCR Apr 2024 30.000 callMarch 9, 2024 | finance.yahoo.comXNCR May 2024 22.500 putMarch 7, 2024 | finance.yahoo.comInsider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)March 1, 2024 | markets.businessinsider.comXencor’s Strategic Focus and Pipeline Progress Affirm Buy RatingMarch 1, 2024 | msn.comPiper Sandler Downgrades Xencor (XNCR)February 29, 2024 | morningstar.comXencor Inc XNCRFebruary 29, 2024 | finance.yahoo.comXencor Full Year 2023 Earnings: Misses ExpectationsSee More Headlines Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/12/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$36.25 High Stock Price Target$50.00 Low Stock Price Target$24.00 Potential Upside/Downside+61.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-82.23% Pretax Margin-71.55% Return on Equity-19.83% Return on Assets-15.94% Debt Debt-to-Equity Ratio0.02 Current Ratio7.36 Quick Ratio7.36 Sales & Book Value Annual Sales$168.34 million Price / Sales8.23 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book2.05Miscellaneous Outstanding Shares61,650,000Free Float58,423,000Market Cap$1.39 billion OptionableOptionable Beta0.77 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Bassil I. Dahiyat Ph.D. (Age 54)Co-Founder, CEO, President & Director Comp: $1.07MDr. John R. Desjarlais Ph.D. (Age 60)Executive VP of Research & Chief Scientific Officer Comp: $748.65kMs. Celia E. Eckert J.D. (Age 51)Senior VP, General Counsel & Corporate Secretary Comp: $641.85kDr. Nancy Valente M.D. (Age 65)Executive VP & Chief Development Officer Comp: $797.68kMr. Bart Jan CornelissenSenior VP & CFOMr. Charles LilesAssociate Director and Head of Corporate Communications & Investor RelationsMs. Jennifer SandozSenior VIce President of Human ResourcesDr. Jeremy Grunstein Ph.D.Senior Vice President of Business DevelopmentMr. Kirk Rosemark RAC (Age 59)Senior Vice President of Regulatory Affairs & Quality Assurance Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance ManagementMore ExecutivesKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNMorphicNASDAQ:MORFProtagonist TherapeuticsNASDAQ:PTGXAkero TherapeuticsNASDAQ:AKRODynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 243,793 shares on 5/10/2024Ownership: 11.373%Acadian Asset Management LLCBought 9,374 shares on 5/10/2024Ownership: 0.015%State Board of Administration of Florida Retirement SystemBought 4,990 shares on 5/9/2024Ownership: 0.035%Mitsubishi UFJ Asset Management Co. Ltd.Sold 541 shares on 5/9/2024Ownership: 0.020%ProShare Advisors LLCBought 1,203 shares on 5/8/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions XNCR Stock Analysis - Frequently Asked Questions Should I buy or sell Xencor stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price target for 2024? 9 equities research analysts have issued 12 month target prices for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they anticipate the company's stock price to reach $36.25 in the next year. This suggests a possible upside of 61.3% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2024? Xencor's stock was trading at $21.23 on January 1st, 2024. Since then, XNCR stock has increased by 5.9% and is now trading at $22.48. View the best growth stocks for 2024 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.28. The biopharmaceutical company had revenue of $12.80 million for the quarter, compared to analysts' expectations of $23.07 million. Xencor had a negative net margin of 82.23% and a negative trailing twelve-month return on equity of 19.83%. The company's revenue for the quarter was down 32.3% on a year-over-year basis. During the same period last year, the firm earned ($1.02) EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Invesco S&P SmallCap Health Care ETF (PSCH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).iShares Genomics Immunology and Healthcare ETF (IDNA). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). Who are Xencor's major shareholders? Xencor's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.37%), Principal Financial Group Inc. (0.53%), Russell Investments Group Ltd. (0.36%), Mutual of America Capital Management LLC (0.15%), Texas Permanent School Fund Corp (0.09%) and BNP Paribas Financial Markets (0.07%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XNCR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceThe A.I. story nobody is telling you (Read ASAP)TradeSmithObama’s Forever Term [exposed]Porter & CompanyThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
